Basilar Artery Occlusion Chinese Endovascular Trial in Patients With Large Core Infarct (NCT07046299) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Basilar Artery Occlusion Chinese Endovascular Trial in Patients With Large Core Infarct
China314 participantsStarted 2025-07-01
Plain-language summary
This study evaluates the safety and efficacy of endovascular therapy for acute basilar artery occlusion with large core infarcts in a multicenter randomized trial.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Posterior circulation acute ischemic stroke within 24 hours from symptom onset/last seen well.
✓. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
✓. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 3-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
✓. Age ≥18 and ≤80 years.
✓. Baseline NIHSS score ≥6 at the time of randomization.
✓. Informed consent obtained from patient or acceptable patient surrogate.
Exclusion criteria
✕. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 3.0.
✕. Baseline platelet count \< 50000/µL.
✕. Baseline blood glucose of \< 50mg/dL or \>400mg/dL.
✕. Severe, sustained hypertension (SBP \> 220 mm Hg or DBP \> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.
What they're measuring
1
Proportion of Patients Achieving mRS 0-3 at 90 Days